Quote this publication Share Print

XALKORI

-
Opinions on drugs - Posted on Jul 10 2013

Reason for request

Inclusion

-


Actual benefit

Important

The actual benefit is substantial in the second-line treatment of ALK+ advanced non-small cell lung cancer (NSCLC).


Improvement in actual benefit

III (modéré)

XALKORI provides a moderate improvement in actual benefit (level III) in the treatment strategy of ALK+ advanced non-small cell lung cancer as a second-line therapy and compared with docetaxel or pemetrexed.


Contact Us

Évaluation des médicaments

See also